659 related articles for article (PubMed ID: 25695169)
41. Clinical characteristics and risk factors for community-acquired Clostridium difficile infection: A retrospective, case-control study in a tertiary care hospital in Japan.
Mori N; Aoki Y
J Infect Chemother; 2015 Dec; 21(12):864-7. PubMed ID: 26482373
[TBL] [Abstract][Full Text] [Related]
42. Clinical manifestations of Clostridium difficile infection in a medical center in Taiwan.
Lai CC; Lin SH; Tan CK; Liao CH; Huang YT; Hsueh PR
J Microbiol Immunol Infect; 2014 Dec; 47(6):491-6. PubMed ID: 23978490
[TBL] [Abstract][Full Text] [Related]
43. High morbidity and mortality of Clostridium difficile infection and its associations with ribotype 002 in Hong Kong.
Wong SH; Ip M; Hawkey PM; Lo N; Hardy K; Manzoor S; Hui WW; Choi KW; Wong RY; Yung IM; Cheung CS; Lam KL; Kwong T; Wu WK; Ng SC; Wu JC; Sung JJ; Lee N
J Infect; 2016 Aug; 73(2):115-22. PubMed ID: 27246801
[TBL] [Abstract][Full Text] [Related]
44. Validation of a clinical prediction scale for hospital-onset Clostridium difficile infection.
Chandra S; Thapa R; Marur S; Jani N
J Clin Gastroenterol; 2014; 48(5):419-22. PubMed ID: 24172178
[TBL] [Abstract][Full Text] [Related]
45. Molecular epidemiology of Clostridium difficile infections in children: a retrospective cohort study.
Kociolek LK; Patel SJ; Shulman ST; Gerding DN
Infect Control Hosp Epidemiol; 2015 Apr; 36(4):445-51. PubMed ID: 25782900
[TBL] [Abstract][Full Text] [Related]
46. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital.
Kallen AJ; Thompson A; Ristaino P; Chapman L; Nicholson A; Sim BT; Lessa F; Sharapov U; Fadden E; Boehler R; Gould C; Limbago B; Blythe D; McDonald LC
Infect Control Hosp Epidemiol; 2009 Mar; 30(3):264-72. PubMed ID: 19215193
[TBL] [Abstract][Full Text] [Related]
47. Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection.
McDonald EG; Milligan J; Frenette C; Lee TC
JAMA Intern Med; 2015 May; 175(5):784-91. PubMed ID: 25730198
[TBL] [Abstract][Full Text] [Related]
48. Clostridium difficile infection in the "oldest" old: clinical outcomes in patients aged 80 and older.
Cober ED; Malani PN
J Am Geriatr Soc; 2009 Apr; 57(4):659-62. PubMed ID: 19392957
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of the Clostridium difficile BI/NAP1/027 strain across the United States Veterans Health Administration.
Giancola SE; Williams RJ; Gentry CA
Clin Microbiol Infect; 2018 Aug; 24(8):877-881. PubMed ID: 29174729
[TBL] [Abstract][Full Text] [Related]
50. Risk factors of Clostridium difficile infections among patients in a university hospital in Shanghai, China.
Huang H; Wu S; Chen R; Xu S; Fang H; Weintraub A; Nord CE
Anaerobe; 2014 Dec; 30():65-9. PubMed ID: 25219941
[TBL] [Abstract][Full Text] [Related]
51. Epidemiology of suspected Clostridium difficile-associated hospital-acquired diarrhea in hospitalized patients at Siriraj Hospital.
Thipmontree W; Kiratisin P; Manatsathit S; Thamlikitkul V
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S207-16. PubMed ID: 21721449
[TBL] [Abstract][Full Text] [Related]
52. Risk of Clostridium difficile infection in hospitalized patients receiving metronidazole for a non-C difficile infection.
Rodriguez S; Hernandez MB; Tarchini G; Zaleski M; Vatanchi M; Cardona L; Castro-Pavia F; Schneider A
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1856-61. PubMed ID: 24681079
[TBL] [Abstract][Full Text] [Related]
53. Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027.
Wieczorkiewicz JT; Lopansri BK; Cheknis A; Osmolski JR; Hecht DW; Gerding DN; Johnson S
Antimicrob Agents Chemother; 2016 Jan; 60(1):418-23. PubMed ID: 26525793
[TBL] [Abstract][Full Text] [Related]
54. Proton Pump Inhibitors and the Risk for Hospital-Acquired Clostridium difficile Infection.
Barletta JF; El-Ibiary SY; Davis LE; Nguyen B; Raney CR
Mayo Clin Proc; 2013 Oct; 88(10):1085-90. PubMed ID: 24012413
[TBL] [Abstract][Full Text] [Related]
55. Current strategies for management of initial Clostridium difficile infection.
Kelly CP
J Hosp Med; 2012 Mar; 7 Suppl 3():S5-10. PubMed ID: 22407996
[TBL] [Abstract][Full Text] [Related]
56. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain.
O'Connor JR; Johnson S; Gerding DN
Gastroenterology; 2009 May; 136(6):1913-24. PubMed ID: 19457419
[TBL] [Abstract][Full Text] [Related]
57. C. difficile infection (CDI) in a long-term acute care facility (LTAC).
Goldstein EJ; Polonsky J; Touzani M; Citron DM
Anaerobe; 2009 Dec; 15(6):241-3. PubMed ID: 19683064
[TBL] [Abstract][Full Text] [Related]
58. Clinical features and characteristics of Clostridium difficile PCR-ribotype 176 infection: results from a 1-year university hospital internal ward study.
Drabek J; Nyc O; Krutova M; Stovicek J; Matejkova J; Keil R
Ann Clin Microbiol Antimicrob; 2015 Dec; 14():55. PubMed ID: 26698842
[TBL] [Abstract][Full Text] [Related]
59. Polymerase chain reaction assay to detect Clostridium difficile tcdC variants is valuable in characterizing hospital epidemiology.
Wilmer A; Lloyd-Smith E; Leung V; Wong T; Ritchie G; Hoang L; Champagne S; Romney MG
J Hosp Infect; 2013 Jul; 84(3):252-5. PubMed ID: 23702278
[TBL] [Abstract][Full Text] [Related]
60. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
